181 related articles for article (PubMed ID: 33543397)
21. Removal of corneal crystals by topical cysteamine in nephropathic cystinosis.
Kaiser-Kupfer MI; Fujikawa L; Kuwabara T; Jain S; Gahl WA
N Engl J Med; 1987 Mar; 316(13):775-9. PubMed ID: 3821824
[TBL] [Abstract][Full Text] [Related]
22. Gel formulations for treatment of the ophthalmic complications in cystinosis.
Buchan B; Kay G; Heneghan A; Matthews KH; Cairns D
Int J Pharm; 2010 Jun; 392(1-2):192-7. PubMed ID: 20382212
[TBL] [Abstract][Full Text] [Related]
23. A randomised placebo-controlled trial of topical cysteamine therapy in patients with nephropathic cystinosis.
Bradbury JA; Danjoux JP; Voller J; Spencer M; Brocklebank T
Eye (Lond); 1991; 5 ( Pt 6)():755-60. PubMed ID: 1800180
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride.
Liang H; Labbé A; Baudouin C; Plisson C; Giordano V
Br J Ophthalmol; 2021 May; 105(5):608-613. PubMed ID: 32593979
[TBL] [Abstract][Full Text] [Related]
25. [1H-NMR spectroscopic study of cysteamine eyedrops].
Gräf M; Kalinowski HO
Klin Monbl Augenheilkd; 1995 Apr; 206(4):262-5. PubMed ID: 7791287
[TBL] [Abstract][Full Text] [Related]
26. Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis.
McKenzie B; Kay G; Matthews KH; Knott R; Cairns D
Int J Pharm; 2016 Dec; 515(1-2):575-582. PubMed ID: 27771488
[TBL] [Abstract][Full Text] [Related]
27. Nephropathic cystinosis in children: An overlooked disease.
Soliman NA; El-Baroudy R; Rizk A; Bazaraa H; Younan A
Saudi J Kidney Dis Transpl; 2009 May; 20(3):436-42. PubMed ID: 19414947
[TBL] [Abstract][Full Text] [Related]
28. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
[TBL] [Abstract][Full Text] [Related]
29. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis.
Levtchenko EN; van Dael CM; de Graaf-Hess AC; Wilmer MJ; van den Heuvel LP; Monnens LA; Blom HJ
Pediatr Nephrol; 2006 Jan; 21(1):110-3. PubMed ID: 16252107
[TBL] [Abstract][Full Text] [Related]
30.
Ozdemir HB; Özmen MC; Aktas Z; Hasanreisoglu M
Indian J Ophthalmol; 2019 Jan; 67(1):153-155. PubMed ID: 30574930
[TBL] [Abstract][Full Text] [Related]
31. Effects of long-term cysteamine treatment in patients with cystinosis.
Ariceta G; Giordano V; Santos F
Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
[TBL] [Abstract][Full Text] [Related]
32. Ophthalmic Outcome in a Belgian Cohort of Cystinosis Patients Treated with a Compounded Preparation of Cysteamine Eye Drops: Retrospective Analysis.
Peeters F; Cassiman C; Van Keer K; Levtchenko E; Veys K; Casteels I
Ophthalmol Ther; 2019 Dec; 8(4):623-633. PubMed ID: 31560113
[TBL] [Abstract][Full Text] [Related]
33. Suppository formulations as a potential treatment for nephropathic cystinosis.
Buchan B; Kay G; Matthews KH; Cairns D
J Pharm Sci; 2012 Oct; 101(10):3729-38. PubMed ID: 22778070
[TBL] [Abstract][Full Text] [Related]
34. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
[TBL] [Abstract][Full Text] [Related]
35. Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%.
Jones NP; Postlethwaite RJ; Noble JL
Br J Ophthalmol; 1991 May; 75(5):311-2. PubMed ID: 2036352
[TBL] [Abstract][Full Text] [Related]
36. A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis.
Kaiser-Kupfer MI; Gazzo MA; Datiles MB; Caruso RC; Kuehl EM; Gahl WA
Arch Ophthalmol; 1990 May; 108(5):689-93. PubMed ID: 2185723
[TBL] [Abstract][Full Text] [Related]
37. A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.
Berends CL; Pagan L; van Esdonk MJ; Klarenbeek NB; Bergmann KR; Moerland M; van der Wel V; de Visser SJ; Büller H; de Loos F; de Vries WS; Waals H; de Leede LGJ; Burggraaf J; Kamerling IMC
Pharmacol Res Perspect; 2021 Apr; 9(2):e00739. PubMed ID: 33764642
[TBL] [Abstract][Full Text] [Related]
38. Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients.
Klank S; van Stein C; Grüneberg M; Ottolenghi C; Rauwolf KK; Grebe J; Reunert J; Harms E; Marquardt T
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514038
[TBL] [Abstract][Full Text] [Related]
39. Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops.
Reda A; Van Schepdael A; Adams E; Paul P; Devolder D; Elmonem MA; Veys K; Casteels I; van den Heuvel L; Levtchenko E
JIMD Rep; 2018; 42():47-51. PubMed ID: 29214524
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Topical Cysteamine in Corneal Cystinosis: A Systematic Review and Meta-Analysis.
Kaur S; Sarma P; Kaur H; Prajapat M; Shekhar N; Bhattacharyya J; Kaur H; Kumar S; Medhi B; Ram J; Das D; Avti P; Prakash A; Singh R; Bhattacharyya A
Am J Ophthalmol; 2021 Mar; 223():275-285. PubMed ID: 32888903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
